754 Adjuvant radiotherapy for male breast cancer: insights from a 35-year single-institutional cohort
Luisa Bellu(Sorbonne Université), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Sara Talomo(Istituto Oncologico Veneto), Alessandro Parisi(Marche Polytechnic University), Francesca Porra(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Massimo Ferrucci(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Marco Krengli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Federica Guida(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Enrica Bovo, Maria Vittoria Dieci(University of Padua), F. Busato(Istituto Oncologico Veneto), Francesco Pasqualetti, Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226